By On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.
Top News
- Pain and Arthritis Products Containing Hidden Ingredients
- Painflex Forte may be harmful due to hidden drug ingredients
- reBom Co., Ltd. – 682811 – 06/26/2024
- Max Chemical Inc. – 682037 – 06/20/2024
- Cholrem Pty Ltd dba Cholrem and Cholrem Pharmaceuticals – 684036 – 07/09/2024
- YangZhou SuXiang Medical Instrument Co., Ltd. – 686655 – 07/08/2024
- 6 Things to Do in Ennis, Texas—From Bluebonnet Trails to a Railroad Museum
- ATM Glitch is Causing Chase to Sue Over 1,000 People—Were You Part of It?
- She Rescued a Dog on a Mountain—And He Rescued Her Family, Too
- April 21 to April 27 Horoscope Forecast: Your Zodiac Sign’s Week
- More Money Found: 11 Refunds and Credits You Can Get on Common Expenses
- 8-Year-Old Makes Easter Baskets for Hundreds of Kids in Need!
- China jumpstarts humanoid robot production with EV sector support
- Taiwan taps private sector for unmanned naval defense push
- CATL to mass-produce first sodium-ion battery by year-end
- Foxconn unveils AI-integrated EV, marking major push into global auto market
- Tesla’s 2025 slowdown reveals limits of the Musk playbook
- Taiwan rides AI wave as US tech orders surge
